Researchers determined the presence of pulmonary hypertension was associated with worse outcomes for patients with polycythemia vera.

We are thrilled to welcome Jay to the Agios Board of Directors,” said Brian Goff, Chief Executive Officer, Agios. “His deep scientific insight, extensive regulatory expertise, and strategic business ...

Panelists discuss how the future treatment landscape for myeloproliferative neoplasms is evolving with many promising ...

Panelists discuss how rusfertide, a hepcidin mimetic peptide, shows promise in polycythemia vera by reducing phlebotomy ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Discover the critical importance of vitamin B12 in combating fatigue and maintaining overall health. Cardiologist Dr. Alok Chopra explores dietary sources, deficiency signs, and the risks for ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry nears.

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the ...

Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now. Just as June began, Protagonist Therapeutics and Takeda Pharmaceutical Company Limited (NYSE:TAK) ...

People will frown at you; they will mock you and will often tell you go to bed earlier and not sleep on the job.

Detailed price information for Protagonist Therapeutics Inc (PTGX-Q) from The Globe and Mail including charting and trades.